BR112020008531A2 - compostos antibacterianos - Google Patents

compostos antibacterianos Download PDF

Info

Publication number
BR112020008531A2
BR112020008531A2 BR112020008531-6A BR112020008531A BR112020008531A2 BR 112020008531 A2 BR112020008531 A2 BR 112020008531A2 BR 112020008531 A BR112020008531 A BR 112020008531A BR 112020008531 A2 BR112020008531 A2 BR 112020008531A2
Authority
BR
Brazil
Prior art keywords
alkyl
group
phenyl
cycloalkyl
cia
Prior art date
Application number
BR112020008531-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Meo
Nawaz KHAN
Cedric Charrier
Original Assignee
Discuva Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020008531(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd. filed Critical Discuva Ltd.
Publication of BR112020008531A2 publication Critical patent/BR112020008531A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Warehouses Or Storage Devices (AREA)
BR112020008531-6A 2017-11-03 2018-11-02 compostos antibacterianos BR112020008531A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718285.8 2017-11-03
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (1)

Publication Number Publication Date
BR112020008531A2 true BR112020008531A2 (pt) 2020-10-20

Family

ID=60664899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020008531-6A BR112020008531A2 (pt) 2017-11-03 2018-11-02 compostos antibacterianos

Country Status (23)

Country Link
US (2) US11345694B2 (enExample)
EP (2) EP3704105B9 (enExample)
JP (2) JP7348897B2 (enExample)
KR (1) KR102470319B1 (enExample)
CN (1) CN111566099B (enExample)
AU (1) AU2018361828B2 (enExample)
BR (1) BR112020008531A2 (enExample)
CA (1) CA3081423A1 (enExample)
CL (2) CL2020001147A1 (enExample)
CO (1) CO2020005420A2 (enExample)
EA (1) EA202091118A1 (enExample)
ES (1) ES3005164T3 (enExample)
GB (1) GB201718285D0 (enExample)
GE (1) GEP20237522B (enExample)
IL (1) IL274229B2 (enExample)
MA (1) MA50504A (enExample)
MX (2) MX2020004562A (enExample)
NZ (1) NZ764310A (enExample)
PE (2) PE20221006A1 (enExample)
SG (1) SG11202003717UA (enExample)
UA (1) UA128475C2 (enExample)
WO (1) WO2019086890A1 (enExample)
ZA (1) ZA202002093B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
HUE066783T2 (hu) 2018-04-18 2024-09-28 Constellation Pharmaceuticals Inc Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
US20240228474A1 (en) 2021-05-03 2024-07-11 Discuva Limited Antibacterial compound
US20250161980A1 (en) 2022-02-21 2025-05-22 Mitsui Chemicals, Inc. Metal member, metal-resin composite body, and method for producing metal member
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
RU2367661C2 (ru) * 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (en) * 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
CN103764655B (zh) * 2011-07-13 2017-04-12 Sk化学公司 作为alk5和/或alk4抑制剂的经2‑吡啶基取代的咪唑
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
CN116942832A (zh) * 2014-05-16 2023-10-27 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
BR112017017135A2 (pt) 2015-03-02 2018-04-03 Rigel Pharmaceuticals, Inc. inibidores de tgf-beta
WO2016141381A2 (en) 2015-03-05 2016-09-09 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
EA202091118A1 (ru) 2020-08-06
ES3005164T9 (en) 2025-03-24
IL274229B2 (en) 2023-05-01
UA128475C2 (uk) 2024-07-24
EP3704105B1 (en) 2024-10-16
JP7348897B2 (ja) 2023-09-21
CN111566099B (zh) 2023-06-02
US11345694B2 (en) 2022-05-31
NZ764310A (en) 2023-04-28
AU2018361828B2 (en) 2023-05-18
AU2018361828A1 (en) 2020-05-28
IL274229B1 (en) 2023-01-01
JP2021501756A (ja) 2021-01-21
EP4606375A2 (en) 2025-08-27
EP4606375A3 (en) 2025-11-19
MX2021010246A (es) 2021-09-21
SG11202003717UA (en) 2020-05-28
MA50504A (fr) 2020-09-09
GEP20237522B (en) 2023-08-10
KR102470319B1 (ko) 2022-11-25
PE20211390A1 (es) 2021-07-27
WO2019086890A1 (en) 2019-05-09
CL2020001147A1 (es) 2020-08-14
MX2020004562A (es) 2020-08-13
GB201718285D0 (en) 2017-12-20
EP3704105B9 (en) 2025-03-05
US20220372027A1 (en) 2022-11-24
PE20221006A1 (es) 2022-06-15
KR20200084875A (ko) 2020-07-13
CN111566099A (zh) 2020-08-21
IL274229A (en) 2020-06-30
CA3081423A1 (en) 2019-05-09
US20210163460A1 (en) 2021-06-03
ES3005164T3 (en) 2025-03-14
ZA202002093B (en) 2023-11-29
CL2021002263A1 (es) 2022-04-01
EP3704105A1 (en) 2020-09-09
CO2020005420A2 (es) 2020-07-31
JP2022025116A (ja) 2022-02-09

Similar Documents

Publication Publication Date Title
BR112020008531A2 (pt) compostos antibacterianos
TWI827646B (zh) Ptpn11抑制劑
RU2667907C9 (ru) ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
JP2011520832A5 (enExample)
BR112021008991A2 (pt) derivados de 2,3-di-hidro-1h-pirrolo [3,4c]piridin-1-ona como inibidores de hpk1 para o tratamento de câncer
KR20180022833A (ko) 항균성 화합물
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
EP3057953A1 (en) Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
AU2014337154A1 (en) Co-crystals of (s)-N-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as DNA-PK inhibitors
WO2015138902A1 (en) Combination therapy with glutaminase inhibitors
UA121747C2 (uk) Фармацевтичні сполуки
MX2009013501A (es) Compuestos piperidinicos y sus usos.
AR068111A1 (es) Compuesto de pirazina y piperidina piperazinil sustituida, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
US20240239809A1 (en) Therapeutic agents for enhancing epithelial and/or endothelial barrier function
MX2012006287A (es) Activadores de azaindol glucocinasa.
ES2369662T3 (es) Derivados de bencimidazol sustituidos con fenilo en la posición 1 y heteroarilo en la posición 2 y su utilización para la preparación de medicamentos destinados al tratamiento de enfermedades inmunológicas.
BR112020014875A2 (pt) Composto cíclico condensado tendo antagonismo de receptor de dopamina d3
EA041456B1 (ru) Антибактериальные соединения
US20250074916A1 (en) Brm targeting compounds and associated methods of use
TW201343614A (zh) 水楊酸苯胺衍生小分子之醫藥組合物及其製備與醫藥用途
BRPI0807799A2 (pt) " derivados de 2-piperazin-1-il-3h-imidazo{4,5-b]piridina".
TN2013000084A1 (fr) Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques quui les contiennent

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: DISCUVA LTD. (GB)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]